In a report released yesterday, Mayank Mamtani from B.Riley FBR reiterated a Buy rating on Intercept Pharma (ICPT – Research Report). The company’s shares closed yesterday at $117.34. Mamtani commented: “Sciences, Inc. announced negative results from their Ph. III STELLAR-4